A share price of Mural Oncology plc [MURA] is currently trading at $2.70, up 11.57%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MURA shares have gain 171.30% over the last week, with a monthly amount drifted -34.31%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Mural Oncology plc [NASDAQ: MURA] stock has seen the most recent analyst activity on March 25, 2025, when Raymond James downgraded its rating to a Outperform but kept the price target unchanged to $18 for it. Previously, Morgan Stanley downgraded its rating to Equal-Weight on March 25, 2025. On June 28, 2024, Rodman & Renshaw initiated with a Buy rating and assigned a price target of $15 on the stock. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $13 on April 04, 2024.
Mural Oncology plc experienced fluctuations in its stock price throughout the past year between $0.95 and $4.74. Mural Oncology plc [NASDAQ: MURA] shares were valued at $2.70 at the most recent close of the market.
Analyzing the MURA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.76, Equity is -0.68 and Total Capital is -0.97. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.49 points at the first support level, and at 2.29 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.84, and for the 2nd resistance point, it is at 2.99.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Mural Oncology plc [NASDAQ:MURA] is 5.83. As well, the Quick Ratio is 5.83, while the Cash Ratio is 4.41.
Transactions by insiders
Recent insider trading involved Loew Caroline, Officer, that happened on Mar 04 ’25 when 4313.0 shares were purchased., Keson-Brookes Maiken completed a deal on Mar 05 ’25 to sell 1469.0 shares. Meanwhile, Keson-Brookes Maiken sold 1262.0 shares on Mar 04 ’25.
